The Supervisory Board of Sartorius AG has resolved to extend the appointment of Dr. René Fáber as a member of the Executive Board by a five-year period to December 31, 2031. This decision maintains leadership stability for the Bioprocess Solutions Division, which Fáber has overseen since joining the Executive Board in January 2019. The extension signals confidence in Fáber's strategic direction during a period of significant expansion in the biopharmaceutical industry.
Fáber, who holds a Ph.D. in polymer chemistry from the Technical University of Munich, joined Sartorius as a scientist in 2002 and progressed through several management positions before his executive appointment. His continued leadership is particularly important as Sartorius strengthens its position as a leading international partner to biopharmaceutical research and manufacturing industries. The company's Bioprocess Solutions Division provides critical single-use solutions for safer, faster, and more sustainable production of biotech drugs, vaccines, and cell and gene therapies.
The timing of this extension coincides with Sartorius's continued growth trajectory, following 2025 sales revenue of approximately 3.5 billion euros. With around 60 production and sales locations worldwide and more than 14,000 employees serving global customers, leadership continuity supports the company's strategic initiatives. Sartorius regularly supplements its portfolio through acquisitions of complementary technologies, requiring consistent executive oversight to integrate new capabilities effectively.
This board extension occurs as Sartorius prepares to report quarterly financial results, with the first quarter 2026 results scheduled for publication on April 23, 2026. Additional financial reporting dates include half-year results on July 23, 2026, and nine-month results on October 22, 2026. These regular financial disclosures provide transparency to stakeholders about the company's performance under current leadership. More information about the company's activities and leadership can be found through their newsroom or by following them on LinkedIn.
The extension of Fáber's appointment through 2031 ensures that Sartorius maintains experienced leadership during a transformative period for the biopharmaceutical sector. As the industry continues to evolve with advances in biotechnology and increased demand for innovative therapies, consistent executive guidance becomes increasingly valuable. This decision reflects the Supervisory Board's assessment that Fáber's expertise and institutional knowledge position him to effectively lead the Bioprocess Solutions Division through upcoming challenges and opportunities in the global market.
